Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.68 USD

0.68
1,013,281

-0.02 (-2.59%)

Updated May 22, 2019 03:58 PM ET

Pre-Market: $0.68 -0.01 (-0.73%) 8:38 AM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.08%
18.07%
9.73%
5.25%
2.19%
10.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for AVEO

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for AVEO Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 24 34 23 34 55
Receivables 3 15 1 5 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 0 1 2 2 1
Total Current Assets 28 50 26 40 59
Net Property & Equipment 0 0 0 0 11
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 1 0 0
Total Assets 28 50 27 41 71
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 3 0 2 2 12
Accounts Payable 4 2 2 1 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 9 11 4 4 14
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 19 2 5 11
Total Current Liabilities 18 32 10 12 40
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 1 2 3 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 16 18 12 7 9
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 17 39 5 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 55 91 29 23 50
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 568 546 520 512 501
Retained Earnings -595 -587 -522 -495 -480
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -27 -41 -2 17 21
Total Liabilities & Shareholder's Equity 28 50 27 41 71
Total Common Equity -27 -41 -2 17 21
Shares Outstanding 125.30 118.30 75.90 58.00 52.20
Book Value Per Share -0.22 -0.34 -0.03 0.30 0.39

Fiscal Year End for AVEO Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018
Assets          
Cash & Equivalents NA 24 20 18 27
Receivables NA 3 0 1 16
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 0 1 1 1
Total Current Assets NA 28 21 20 44
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 28 21 20 44
Liabilities & Shareholders Equity 3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018
Notes Payable NA 3 4 2 1
Accounts Payable NA 4 3 3 3
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 9 10 9 9
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 2 2 3 19
Total Current Liabilities NA 18 19 17 32
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 4 3 4 4
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 16 15 16 18
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 44 28 39
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 55 82 65 94
Shareholders Equity 3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 568 556 549 548
Retained Earnings NA -595 -617 -595 -599
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -27 -60 -45 -50
Total Liabilities & Shareholder's Equity NA 28 21 20 44
Total Common Equity 0 -27 -60 -45 -50
Shares Outstanding 160.70 125.30 119.00 118.90 118.80
Book Value Per Share 0.00 -0.22 -0.51 -0.38 -0.42